CLINDA-DERM
Clinical safety rating: caution
Comprehensive clinical and safety monograph for CLINDA-DERM (CLINDA-DERM).
Clindamycin binds to the 50S ribosomal subunit of bacteria, inhibiting protein synthesis by interfering with peptide chain formation. It has bacteriostatic activity against susceptible organisms.
| Metabolism | Clindamycin is metabolized primarily in the liver via oxidation and conjugation. Major metabolite is N-demethylclindamycin and clindamycin sulfoxide. Enzymes: CYP3A4 plays a minor role. |
| Excretion | Primarily renal (10-20% unchanged; remainder as metabolites) and biliary/fecal (approximately 40-50% of dose as metabolites in feces). |
| Half-life | 2-4 hours (terminal half-life) in adults with normal renal function; prolonged in hepatic impairment (up to 8-12 hours) and severe renal impairment. |
| Protein binding | 90-95% bound primarily to albumin; also binds to alpha-1-acid glycoprotein. |
| Volume of Distribution | 0.6-1.0 L/kg, indicating distribution into total body water with higher concentrations in tissues such as bone and abscesses. |
| Bioavailability | Topical: limited systemic absorption (~10-15% of applied dose); oral: 90-95% bioavailable; intramuscular: 100% bioavailable. |
| Onset of Action | Topical: within 1-2 weeks of regular application for acne vulgaris; systemic (oral): 1-2 hours for peak serum concentrations. |
| Duration of Action | Topical: sustained effect with continued application; systemic: dosing interval 6-8 hours to maintain therapeutic levels. |
Topical: Apply a thin film to affected area twice daily. For acne vulgaris, available as 1% gel, lotion, or solution.
| Dosage form | SOLUTION |
| Renal impairment | No dose adjustment required for renal impairment due to minimal systemic absorption. |
| Liver impairment | No dose adjustment required for hepatic impairment due to minimal systemic absorption. |
| Pediatric use | Pediatric patients (age 12 and older): Same as adult dosing. For children <12 years, safety and efficacy not established; use only if clearly needed. |
| Geriatric use | No specific geriatric adjustment required; use caution due to potential skin atrophy with prolonged use. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for CLINDA-DERM (CLINDA-DERM).
| Breastfeeding | Clindamycin is excreted in human milk (M/P ratio approximately 0.4-0.7). Limited data suggest low risk; however, use caution due to potential for gastrointestinal effects or allergic sensitization in the infant. |
| Teratogenic Risk | Pregnancy Category B. No evidence of teratogenicity in animal studies; however, no adequate human studies in first trimester. Clindamycin is considered low risk but should only be used if clearly needed. |
| Fetal Monitoring |
■ FDA Black Box Warning
No FDA boxed warning for topical clindamycin.
| Serious Effects |
["Hypersensitivity to clindamycin or lincomycin.","History of antibiotic-associated colitis."]
| Precautions | ["Clostridium difficile-associated diarrhea (CDAD) reported with systemic use; rare with topical but caution advised.","Avoid contact with eyes, mucous membranes.","May cause skin irritation, dryness.","Use caution in history of gastrointestinal disease.","Prolonged use may lead to overgrowth of non-susceptible organisms."] |
Loading safety data…
| No specific fetal monitoring required. Monitor for maternal adverse effects such as pseudomembranous colitis. |
| Fertility Effects | No known adverse effects on fertility in animal studies. No human data available. |